Orismilast (LEO32731) is a novel, oral and potent PDE4 (phosphodiesterase-4) inhibitor with a broad spectrum of anti-inflammatory activity. It is being investigated in clinical trials for treating atopic dermatitis (AD), psoriasis, hidradenitis suppurativa (HS). It acts early in the inflammation cascade to induce a broad range of anti-inflammatory effects. Orismilast has been selected as lead molecule based on its attractive therapeutic window (i.e., the combination of improved efficacy and tolerability) and because of its potential to inhibit many inflammatory pathways involved in immunologic diseases due to the broad range of anti-inflammatory effects. Over the course of Phase 1 and Phase 2 trials, orismilast has been demonstrated to be safe in both oral and topical dosage forms and the PDE4 mode-of-action has been verified as an effective, well-tolerated approach to treatment of patients across multiple diseases, with no need for monitoring.

纯度：≥98%

CAS：1353546-86-7